SCHEMBL25758544

SCHEMBL25758544

Cc1ccc(-c2ccc(S(=O)(=O)NCCCN3CCC(Cc4ccccc4)CC3)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.69
HTT P42858 1/20 0.69
KMT2A Q03164 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
MBTD1 Q05BQ5 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
HTR1A P08908 2/20 0.58
TMEM97 Q5BJF2 1/20 0.57
KDM4E B2RXH2 1/20 0.56
MAPK1 P28482 1/20 0.56
ATM Q13315 1/20 0.56
SLC6A2 P23975 3/20 0.56
SLC6A4 P31645 3/20 0.56
HTR7 P34969 2/20 0.56
MAPT P10636 1/20 0.52
CARM1 Q86X55 1/20 0.51
PRMT6 Q96LA8 1/20 0.51
KCNH2 Q12809 2/20 0.50
HTR2A P28223 1/20 0.50
HTR2B P41595 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24069429 0.94 SLC6A2 (0.63) MEN1HTTKMT2ASMN1; SMN2SLC6A2
SCHEMBL25290527 0.90 SLC6A2 (0.59) MEN1HTTKMT2ASMN1; SMN2HTR1A
SCHEMBL25758526 0.90 CCR3 (0.58) MEN1HTTKMT2ASMN1; SMN2HTR1A
SCHEMBL25758537 0.90 HTR7 (0.58) MEN1HTTKMT2ASMN1; SMN2SLC6A2
SCHEMBL30376178 0.89 HTR7 (0.69) MEN1HTTKMT2ASMN1; SMN2TMEM97
SCHEMBL25759699 0.89 HTR7 (0.59) MEN1HTTKMT2ASMN1; SMN2HTR1A
SCHEMBL25758458 0.87 SLC6A2 (0.61) MEN1HTTKMT2ASMN1; SMN2KDM4E
SCHEMBL24070124 0.86 MEN1 (0.60) MEN1HTTKMT2ASMN1; SMN2SLC6A2
SCHEMBL25758335 0.85 HTR7 (0.62) MEN1HTTKMT2ASMN1; SMN2HTR1A
SCHEMBL25758331 0.84 MEN1 (0.58) MEN1HTTKMT2ASMN1; SMN2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
EP-4159718-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2023-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 MEN1 2054/4885HTT 618/4885KMT2A 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.